Sonnet BioTherapeutics Holdings, Inc.
SONNDelisted Dec 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001106838
Sonnet BioTherapeutics Holdings, Inc. was delisted on Dec 2, 2025; its insiders filed their last Form 4 on Dec 4, 2025; 27 institutions reported holding it in 13F filings for Q3 2025, worth $3.53M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 27
- Q3 2025, +18 vs. previous quarter
- 13F value
- $3.53M
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Superinvestors holding SONN, Q3 2025
No superinvestor reported holding SONN at the end of Q3 2025.
Latest insider trades
Open-market purchases and sales by Sonnet BioTherapeutics Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2023 (view filing) | Oct 27 | Same day | Rao RaghuDirector | PPurchase | +15.6K | – | – | +1,315.2%16.8K after | |
| Oct 27, 2023 (view filing) | Oct 27 | Same day | Rao RaghuDirector | PPurchase | +31.3K | – | – | –31.3K after | Derivative |
| Oct 27, 2023 (view filing) | Oct 27 | Same day | Mohan PankajChairman, President and CEO | PPurchase | +34.4K | – | – | +136.7%59.5K after | |
| Oct 27, 2023 (view filing) | Oct 27 | Same day | Mohan PankajChairman, President and CEO | PPurchase | +68.8K | – | – | –68.8K after | Derivative |
| Jun 15, 2023 (view filing) | Jun 14 | 1 day | Dexter SusanChief Technical Officer | PPurchase | +10.0K | $0.70 | +$7.00K | +42.3%33.7K after | |
| May 31, 2023 (view filing)8:30 AM ET | May 30 | 1 day | Dyrness Albert D.Director | PPurchase | +23.3K | $0.468 | +$10.9K | +407.5%29.0K after | |
| May 18, 2023 (view filing)8:00 AM ET | May 17 | 1 day | Bhatt NaileshDirector | PPurchase | +25.0K | $0.232 | +$5.80K | +436.1%30.7K after | |
| May 15, 2023 (view filing)5:17 PM ET | May 15 | Same day | Mohan PankajChairman, President and CEO | PPurchase | +371.6K | $0.223 | +$82.9K | +204.5%553.3K after | |
| Mar 16, 2023 (view filing) | Mar 15 | 1 day | Mohan PankajChairman, President and CEO | PPurchase | +60.0K | $0.59 | +$35.4K | +49.3%181.7K after |
Top 10 13F holders, Q3 2025
The largest institutional positions in Sonnet BioTherapeutics Holdings, Inc. at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 150,000 | $687.0K | 0.16% | +150,000 | New |
| Vanguard Group Inc | 96,382 | $441.4K | 0.00% | +96,382 | New |
| HRT Financial LP | 74,265 | $340.0K | 0.00% | +74,265 | New |
| Geode Capital Management, LLC | 61,840 | $283.2K | 0.00% | +36,948+148.4% | Added |
| Boothbay Fund Management, LLC | 56,339 | $258.0K | 0.01% | +56,339 | New |
| Goldman Sachs Group Inc | 55,134 | $252.5K | 0.00% | +55,134 | New |
| BIT Capital GmbH | 48,358 | $221.5K | 0.01% | +48,358 | New |
| Citadel Advisors LLC | 46,082 | $211.1K | 0.00% | +46,082 | New |
| Virtu Financial LLC | 26,266 | $120.0K | 0.01% | +26,266 | New |
| Morgan Stanley | 25,808 | $118.2K | 0.00% | +25,808 | New |